The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation

R Montgomery Gill1, Timothy V Gabor, Amber L Couzens

  • 1Department of Biology, York University, Toronto, Ontario, Canada.

Insights

Cell division control protein A7 (CDCA7) interacts with MYC, but AKT phosphorylation causes its release, affecting MYC-driven cell growth and apoptosis. This reveals a new pathway influencing cancer development.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Cell division control protein A7 (CDCA7) is a MYC transcriptional target.
  • MYC is a key regulator of cell growth and transformation.
  • Understanding CDCA7's role in MYC signaling is crucial for cancer research.

Purpose of the Study:

  • To investigate the interaction between CDCA7 and MYC.
  • To elucidate the role of AKT phosphorylation in modulating CDCA7-MYC association.
  • To determine the functional impact of CDCA7 on MYC-dependent cellular processes.

Main Methods:

  • Co-immunoprecipitation to assess protein interactions.
  • Site-directed mutagenesis to study phosphorylation.
  • Cellular assays for apoptosis and fibroblast transformation.
  • Western blotting and immunofluorescence for protein localization.

Main Results:

  • CDCA7 directly associates with MYC.
  • AKT phosphorylates CDCA7 at Threonine 163, leading to 14-3-3 binding and cytoplasmic sequestration.
  • CDCA7 expression promotes MYC-dependent apoptosis and MYC-induced fibroblast transformation, while a non-interacting mutant inhibits it.

Conclusions:

  • AKT-mediated phosphorylation of CDCA7 disrupts its interaction with MYC.
  • This signaling pathway influences MYC's role in cell survival, apoptosis, and transformation.
  • The findings offer insights into a novel mechanism contributing to MYC-driven tumorigenesis.

Related Concept Videos

Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...